Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency

Atherosclerosis

Volumn 132, Issue 2, 1997, Pages 229-236

  Haraki, Tatsuo ^a   Inazu, Akihiro ^a   Yagi, Kunimasa ^a   Kajinami, Kouji ^a   Koizumi, Junji ^a   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cholesteryl ester transfer protein deficiency; Coronary heart disease; Double heterozygote; Familial hypercholesterolemia

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEFICIENCY;

ADULT; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY DISEASE; FEMALE; GLYCOPROTEINS; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION;

EID: 0030798832     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00093-2     Document Type: Article

References (49)

1. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255.
2. Inazu A, Koizumi J, Haraki T, et al. Rapid detection and prevalence of cholesteryl ester transfer deficiency caused by an intron 14 splicing defect in hyperalphalipoproteinemia. Hum Genet 1993;91:13.
3. Inazu A, Jiang XC, Haraki T, et al. Genetic cholesteryl ester transfer deficiency caused by two prevalent mutations as a major determinant of increased level of high density lipoprotein cholesterol. J Clin Invest 1994;94:1872.
4. Koizumi J, Inazu A, Yagi K, et al. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. Atherosclerosis 1991;90:189.
5. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917.
6. Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinemia. Atherosclerosis 1985;58:175.
7. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234.
8. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw-Hill, 1995:1981.
9. Mabuchi H, Koizumi J, Shimizu M, Takeda R. The Hokuriku FH-CHD study group. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79:225.
10. Ferrieres J, Lambert J, Cacan SL, Davingnon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995;92:290.
11. Mabuchi H, Ito S, Haba T, et al. Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles' tendon thickness. Atherosclerosis 1977;28:61.
12. Vandenplas S, Wild I, Rabie AG, et al. Blot hybridization analysis of genomic DNA. J Med Genet 1984;21:164.
13. Hixon JE, Vernier DI. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545.
14. Marcel YL, McPherson R, Hogue M, et al. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipidemic subjects. J Clin Invest 1990;85:357.
15. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total cholesterol. Clin Chem Acta 1974;20:470.
16. Bucolo G, David H. Quantitative determination of serum triglycérides by use of enzymes. Clin Chem 1973;19:476.
17. Burstein M, Scholnich HR. Lipoprotein-polyanion-metal interactions. Adv Lipid Res 1973;11:67.
18. Friedewald WI, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499.
19. Kajinami K, Mabuchi H, Koizumi J, Takeda R. Serum apolipoproteins in heterozygous familial hypercholesterolemia. Clin Chim Acta 1992;211:93.
20. Cheng ML, Kammerer CM, Lowe WF, Dyke B, VandeBerg JL. Method for quantitating cholesterol in subfractions of serum lipoproteins separated by gradient gel electrophoresis. Biochem Genet 1988;26:657.
21. Brown ML, Inazu A, Hesler CB, et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989;342:448.
22. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311.
23. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (adult treatment panel II). JAMA 1993;269:3015.
24. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982;257:6653.
25. Zeiher AM, Schachinger V, Hohnloser SH, Saubier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivities in humans-elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994;89:2525.
26. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992;89:10316.
27. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein I synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039.
28. Epand RM, Stafford AS, Leon B, et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 1994;14:1775.
29. Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379.
30. Osono Y, Woollett LA, Marotti KR, Melchior GW, Dietschy JM. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci USA 1996;93:4114.
31. Hobbs HH, Leitersdorf E, Lefert CC, Cryer DR, Brown MS, Goldstein JL. Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low density lipoprotein receptors. J. Clin Invest 1989;84:656.
32. Zambon A, Torres A, Bijvoet S, et al. Prevention of raised low-density lipoprotein cholesteol in a patient with a familial hypercholesterolemia and lipoprotein lipase deficiency. Lancet 1993;341:1119.
33. Roberts DCK, Round JM, Loyd JK, Fosbrooke AS. Serum lecithin-cholesterol acyltransferase activity in children with familial hyperbetalipoproteinaemia. Clin Chim Acta 1977;78:311.
34. Inazu A, Koizumi J, Mabuchi H, Kajinami K, Takeda R. Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia. Horm Metab Res 1992;24:284.
35. Marotti KR, Castle CK, Boyle YP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transegenic mice expressing simian cholesteryl ester transfer protein. Nature (London) 1991;364:73.
36. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein. J Clin Invest 1995;96:2071.
37. Ikewaki K, Nishiwaki M, Sakamoto T, et al. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest. 1995;96:1573.
38. Fumeron F, Betoulle D, Luc G, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995;96:1664.
39. Wang XL, McCredie RM, Wilcken DEL. Polymorphism of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol 1995;15:1030.
40. Hirano K, Yamashita S, Kuga Y, et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 1995;15:1849.
41. Oliveira HCF, Ma L, Milne R et al. Cholesteryl ester transfer protein activity enhances plasma cholesteryl ester formation: studies in CETP transgenic mice and human genetic CETP deficiency. Arterioscler Thromb Vasc Biol 1997 (in press).
42. Hoeg JM, S-Fojo S, Berard AM, et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996;93:11448.
43. Shepherd J, Cobbe SM, Foad I, et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301.
44. Sacks FM, Preffer MA, Moye LA, et al. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001.
45. Scandinavian Simvastatin Survival Study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383.
46. Guerin M, Dolphin PJ, Talussot C, Gardette J, Berthezene F, Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1359.
47. Kajinami K, Nishitsuji M, Takeda Y, Shimizu M, Koizumi J, Mabuchi H. Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. Atherosclerosis 1996;120:181.
48. Magoulas LM, Plump A, Jiang XC, Walsh A, Breslow JL, Tall AR. Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein E and low density lipoprotein receptor gene knockout mouse. J Clin Invest 1996;97:154.
49. Sugano M, Makino N. Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits. J Biol Chem 1996;271:19080.